Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16949678 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL5744794 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL26624583 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL16949679 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL30239801 | 0.98 | ALDH1A1 (0.55) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL8399633 | 0.98 | ALDH1A1 (0.55) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL3712279 | 0.98 | ALDH1A1 (0.55) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL23924379 | 0.87 | PTPN1 (0.45) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL5654019 | 0.87 | PTPN1 (0.45) | ALDH1A1MAPTCNR1CNR2PPARA | |
| SCHEMBL22555602 | 0.87 | PTPN1 (0.45) | ALDH1A1MAPTCNR1CNR2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129366-B2 | Group of a novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. (US) | 2006-10-31 | — | — | US | claimed |
| EP-1463707-A4 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2006-02-01 | — | — | EP | claimed |
| US-20040204599-A1 | Group of novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. | 2004-10-14 | — | — | US | claimed |
| EP-1463707-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | Yang, Zhenhua (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2003014296-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2003-02-20 | — | — | WO | claimed |
| US-7129366-B2 | Group of a novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1463707-A4 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040204599-A1 | Group of novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. | 2004-10-14 | — | — | US | disclosed |
| EP-1463707-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | Yang, Zhenhua (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003014296-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204599-A1 | Group of novel anti-cancer compounds with specific structure | FASN, NFKBIA, NFATC1 | ALDH1A1 3568/4885MAPT 4177/4885CNR1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.